利奈唑胺治疗多重耐药结核病的疗效和安全性分析

Analysis of the efficacy and safety of linezolid in the treatment of multi-drug resistant tuberculosis

目的探讨多重耐药结核病临床治疗中应用利奈唑胺的疗效及安全性。方法100例多重耐药结核病患者,根据治疗方式差异性分为对照组及研究组,每组50例。对照组选择多药联合治疗,研究组在对照组的基础上联合利奈唑胺治疗。比较两组临床疗效,临床症状改善时间,不良反应发生情况。结果研究组总有效率88.00%高于对照组的66.00%,差异具有统计学意义(P<0.05)。研究组空洞缩小时间、空洞闭合时间、痰涂片转阴时间、痰培养转阴时间分别为(40.58±5.47)d、(4.57±1.47)个月、(74.29±12.57)d、(49.87±20.29)d,短于对照组的(56.73±3.69)d、(6.89±1.26)个月、(98.52±16.67)d、(87.46±18.52)d,差异具有统计学意义(P<0.05)。两组不良反应发生情况比较,差异无统计学意义(P>0.05)。结论利奈唑胺治疗多重耐药结核病可取得理想的治疗效果,对疾病症状予以有效控制及改善,促进痰菌转阴及空洞闭合,且用药安全性有保障。

Objective To discuss the efficacy and safety of linezolid in the treatment of multi-drug resistant tuberculosis.Methods A total of 100 patients with multidrug-resistant tuberculosis were divided into control group and research group according to the differences of treatment methods,with 50 cases in each group.The control group was treated with multi-drug combination therapy,and the research group was combined with linezolid on the basis of the control group.The clinical efficacy,improvement time of clinical symptoms,and occurrence of adverse reactions were compared between the two groups.Results The total effective rate 88.00%of the research group was higher than 66.00%of the control group,and the difference was statistically significant(P<0.05).The time of cavity reduction,cavity closure time,time of sputum smear negative conversion,and time of sputum culture negative conversion were(40.58±5.47)d,(4.57±1.47)months,(74.29±12.57)d,and(49.87±20.29)d,which were shorter than the control group(56.73±3.69)d,(6.89±1.26)months,(98.52±16.67)d,and(87.46±18.52)d,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the occurrence of adverse reactions between the two groups(P>0.05).Conclusion Linezolid can achieve ideal therapeutic effect,effectively control and improve disease symptoms,promote sputum negative conversion and cavity closure,and the safety of drug use is guaranteed.